Check out these facts about CBD and diabetes to see how this plant can help. One of the most important ways that CBD possibly affects diabetes has These people also had higher levels of high-density lipoprotein cholesterol, as well as insulin resistance . Of every 10 of these dementia patients, six. But while some cholesterol is essential to life, too much can wreak havoc This can occur whether you have diabetes or not, but diabetes patients are at an like Cannabidiol (CBD), further suggests that medical marijuana. A quick Google search of the terms “CBD Oil” and “Diabetes” turns up million hits, with HDL cholesterol and other markers in 62 people with type 2 diabetes. a patient from seeking other therapies that have proven benefits.” Dr. Bhatia says that while CBD oil can have an important role to play in.
cholesterol CBD diabetic is patients for essential and
A study was conducted on rats with infarcts areas of dead tissue due to a failure of blood supply. When pretreated with CBD, these infarcts were 30 per cent smaller. Chronic inflammation has long been known to play a key role in the development of insulin resistance and therefore type 2 diabetes. The researchers believe that the anti-inflammatory properties of CBD could treat this inflammation and therefore improve the body's metabolism.
ISA Scientific, an Israeli company, recently signed a worldwide collaboration and licensing deal to establish therapies containing CBD. Are there side effects? There are no major side effects of CBD, according to Rosenfield, which will not affect patients with diabetes doing everyday activities such as work, driving or exercise.
While CBD can be obtained from marijuana, it is also abundant in hemp, a plant with no psychoactive properties and no potential for abuse. Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts. Also related to this story History of cannabis Treatment for diabetes Driving and diabetes Why is exercise important?
Elderly man who had hypo while driving guided to safety following intervention from motorist Mon, 11 Feb Vitamin C linked to reduced glucose levels in type 2 diabetes Mon, 11 Feb Weight loss surgery puts type 2 diabetes into remission for up to five years Fri, 08 Feb Apps, education and services Diabetes Forum App Find support, ask questions and share your experiences with , members of the diabetes community.
Recipe App Delicious diabetes recipes, updated every Monday. Filter recipes by carbs, calories and time to cook. Low Carb Program Join , people on the award-winning education program for people with type 2 diabetes, prediabetes and obesity.
Hypo Awareness Program The first comprehensive, free and open to all online step-by-step guide to improving hypo awareness. DiabetesPA Your diabetes personal assistant. Monitor every aspect of your diabetes. Independent from macrovascular complications, diabetic cardiomyopathy is a distinct primary disease process that leads to heart failure in diabetic patients.
Diabetic cardiomyopathy is characterized by left ventricular hypertrophy and diastolic dysfunction due to myocardial collagen and advanced glycation end product deposition. CB 1 receptors can mediate oxidative stress and cell death in doxorubicin-induced cardiomyopathy models and in human cardiomyocytes 66,67 ; this damage is enhanced in mice deficient in the main EC, AEA-metabolizing enzyme, FAAH. Although direct involvement of the ECS has not yet been proven in diabetic cardiomyopathy, the plant-derived cannabinoid CBD attenuates inflammation, oxidative stress, cell death, myocardial dysfunction, and fibrosis in a diabetic cardiomyopathy model.
The first direct indication that the ECS plays an important role in the pathogenesis of diabetic nephropathy came from a murine model of metabolic syndrome. This effect was concurrent with a delay in the progression of renal failure as shown by the prevention of the development of proteinuria, improved creatinine clearance, and reduction of glomerular injury and renal hypertrophy compared with vehicle-treated rats.
Similarly, RIO was also able to reduce the albumin-creatinine ratio and glomerular sclerosis in a prediabetic rat model of metabolic syndrome. The selective CB 1 antagonist AM reduced proteinuria by preventing a decrease in the mRNA and protein levels of the slit diaphragm molecules nephrin, podocin, and zonula occludens-1 in diabetic kidneys. CB 2 agonists ameliorated albuminuria, podocyte protein down-regulation, and glomerular monocyte infiltration without affecting early markers of fibrosis and reduced chemokine receptor-2 expression in both the renal cortex and cultured podocytes, suggesting that CB 2 receptor activation may interfere with the deleterious effects of MCP-1 signaling.
The CB 2 receptor was down-regulated in kidney biopsy specimens from patients with advanced diabetic nephropathy, and renal levels of the CB 2 ligand 2-AG were reduced in diabetic mice, suggesting impaired CB 2 signaling.
The in vivo results were supported by in vitro findings that provided more mechanistic insight as to how the ECS influences the pathogenesis of renal failure in diabetes and the role of tubular processes in the effects of ECs during the development of diabetic kidney damage. In vitro , AEA significantly increases the hypertrophy of proximal tubular cells.
In another study, the hyperlipidemia-induced tubular cell dysfunction observed in diabetic kidneys was modeled by palmitic acid—induced apoptosis in HK-2 cells. Blockade of CB 1 receptors was able to ameliorate palmitic acid—induced endoplasmic reticulum stress and the subsequent apoptosis. Diabetes is the leading cause of new cases of blindness and preventable blindness among adults. Vascular inflammation and endothelial cell death caused by oxidative and nitrative stress are characteristics of diabetic retinopathy.
The role of such an increase gained importance when we received insight into the role of CB 1 receptor activation in diabetic retinopathy. Deletion of the CB 1 receptor or treatment with a CB 1 receptor antagonist prevented retinal cell death in a murine diabetes model. These observations were supported by the fact that hyperglycemia up-regulated CB 1 receptor expression and induced apoptosis in retina pigment epithelial cells, effects that were preventable with a CB 1 receptor antagonist.
The effect of CBD was also examined in experimental diabetic retinopathy. CBD was able to reduce oxidative stress, inflammation, cell death, and vascular hyperpermeability associated with diabetes.
Furthermore, CBD also attenuated high glucose—induced endothelial cell dysfunction, ROS generation, and barrier disruption in primary human coronary artery endothelial cells. CB 1 receptors are widely expressed throughout the central and peripheral nervous systems, whereas CB 2 receptors are primarily restricted to the cells of the peripheral nervous system, microglia, and dorsal horn neurons.
ECs are retrograde messengers with agonistic activity on presynaptic CB 1 receptors, slowing neurotransmission. A good example of this effect is the suppression of nociceptive transmission in the periphery at the level of the posterior horn of the spinal cord. The first indication of the role of the ECS in diabetic neuropathy came from a murine diabetes model.
Mechanical allodynia in diabetic rats can also be attenuated by treatment with a nonselective cannabinoid agonist. Both in vitro and in vivo findings regarding the role of cannabinoid receptors in the pathogenesis of diabetic peripheral neuropathy are contradictory. CB 1 receptor expression has been shown to be down-regulated in PC cells exposed to high glucose levels and in dorsal root ganglia removed from diabetic rats 97 ; the synthetic cannabinoid HU was able to restore impaired nerve growth factor—induced neurite outgrowth in cells exposed to high glucose levels in a CB 1 receptor—dependent manner, 98 consistent with the earlier finding that HU attenuates neural damage.
The natural cannabinoid CBD offers a further possible therapeutic advantage because it was able to attenuate the development of neuropathic pain. This effect was associated with the restriction in the elevations of microglial density in the spinal cord and of phosphorylated pMAPK.
Although there is much controversy in the field of EC research, experimental evidence and clinical trials have clearly shown that ECS plays a key role in the development of primary diabetes and various diabetic complications.
Although inhibition of CB 1 receptors has proven to be effective in clinical trials of obesity and metabolic syndrome, this approach has ultimately failed because of increasing patient anxiety. However, recent preclinical studies clearly showed that peripherally restricted CB 1 antagonists may represent a viable therapeutic strategy to avoid the previously mentioned adverse effects.
The main effects of CB 1 receptor activation on the development of diabetes and diabetic complications are summarized in Figure 1. CB 2 agonists may exert beneficial effects on diabetes and diabetic complications by attenuating inflammatory response and ensuing oxidative stress Figure 2. CBD is a potent antioxidant and anti-inflammatory agent that does not appear to exert its beneficial effects through conventional CB receptors and is already approved for human use.
THCV and its derivatives, which may combine the beneficial effects of simultaneous CB 1 inhibition and CB 2 stimulation, are still under intense preclinical investigation. We hope that some of these new approaches will be useful in clinical practice in the near future to aid patients with diabetes. Effects of CB 1 receptor activation on diabetes and diabetic complications.
CB 1 receptor activation may indirectly via its metabolic consequences or directly enhance diabetes-associated inflammation and ROS generation, promoting tissue injury and the development of diabetic complications.
Possible beneficial effects of CB 2 receptor activation on diabetes and diabetic complications. CB 2 receptor stimulation may exert beneficial effects against various diabetic complications by attenuating high glucose—induced endothelial cell activation and inflammatory response; chemotaxis, transmigration, adhesion, and activation of inflammatory cells; and subsequent proinflammatory responses and ROS generation.
We are indebted to Dr. Raphael Mechoulam for critically reading the paper and making valuable suggestions. We apologize to colleagues whose important work may not be covered due to the brief nature of this review. None of the authors disclosed any relevant financial relationships. National Center for Biotechnology Information , U. Journal List Am J Pathol v. Author information Article notes Copyright and License information Disclaimer.
Accepted Nov 2. Published by Elsevier Inc. This document may be redistributed and reused, subject to certain conditions. This article has been cited by other articles in PMC. Abstract Oxidative stress and inflammation play critical roles in the development of diabetes and its complications.
Role of the ECS in Diabetes and Diabetic Complications Primary Diabetes Diabetes is characterized by hyperglycemia caused by either a lack of insulin due to autoimmune destruction of islet cells or insulin resistance. Cardiovascular Complications Accurate glucose, blood pressure, and plasma lipid controls, as well as preventive care practices, are effective in reducing the number of complications in certain patient cohorts with diabetes; however, they have their own limitations.
Diabetic Retinopathy Diabetes is the leading cause of new cases of blindness and preventable blindness among adults. Conclusion and Perspectives Although there is much controversy in the field of EC research, experimental evidence and clinical trials have clearly shown that ECS plays a key role in the development of primary diabetes and various diabetic complications.
Open in a separate window. Acknowledgments We are indebted to Dr. The endocannabinoid system as an emerging target of pharmacotherapy. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. International Union of Basic and Clinical Pharmacology: Is lipid signaling through cannabinoid 2 receptors part of a protective system? The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Curr Opin Investig Drugs. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. The first randomised controlled trial of this kind, published in , found that Sativex a combination of the two main chemical found in the cannabis plant, THC and CBD had no significant effect on pain in 30 patients randomised to Sativex or placebo.
However, a follow up open label study where the patient knows what drug they are taking with patients using Sativex for 38 weeks, showed that the majority of patients found beneficial effects in pain, sleep and global impression of change generally feeling better. THC alone, in the form of the drug Nabilone 4 weeks treatment was also found to be effective in reducing pain in 13 diabetic patients in a double-blind, placebo-controlled study.
A similar result was found recently after smoking THC in a randomised, double-blinded, placebo controlled crossover study in 16 patients , which showed a reduction in pain complications with diabetes. In animal studies, other synthetic CB 1 agonists also reduce pain in models of diabetes.
CBD combination, although larger, multicentre trials are required to confirm this. Animal data discussed below suggest that cannabinoids that activate the CB 2 receptor could also help reduce diabetic-related pain, although this has yet to be tested in humans. One other study has investigated cannabinoid-based medicine in diabetes, published in , which investigated tetrahydrocannabivarin THCV and CBD alone or in combination. This small, double blinded, randomised controlled trial showed that THCV alone 5 mg twice daily decreases blood glucose levels, but CBD mg twice daily had no effect on various markers of diabetes.
THCV is an interesting compound because it has also been shown to improve insulin sensitivity , reduce eating and cause weight loss in animal studies, suggesting further work should be carried out with this compound in diabetic patients.
In addition to the clinical trials above, much research is currently being conducting in the laboratory in cell, tissue and animal studies to further investigate whether novel cannabinoid-based medicines could be useful in the treatment of diabetes. Since , there have been many studies published showing that CBD treatment improves many aspects of diabetes and its complications in animal models.
In rat and mouse models of type 1 diabetes, CBD reduces the incidence and progression of the disease, reduces pain and temperature sensitivity, reduces cardiac heart damage , reduces inflammation at the retina , and reduces pancreatic inflammation , protecting the islet of Langerhans, where insulin is produced. In rat models of type 2 diabetes, CBD also improves vascular function. In cells exposed to high glucose levels, CBD reduces the oxidative stress and inflammatory response.
This evidence all suggests that CBD might be useful in treating both type 1 and 2 diabetes, although the only clinical trial to date did not find any effect of 12 weeks treatment with CBD mg, twice daily in type 2 diabetic patients. However, comparing this dose of CBD against those which have shown that CBD is effective in animal studies, suggest that the dose of CBD used in this clinical trial was potentially too low and a dose-escalation study is required to test higher doses for comparison, epileptic patients take up to 1 g of CBD daily.
As mentioned, activating the CB 1 receptor with THC human trials or various synthetic compounds animal studies reduces pain and heat sensitivity in diabetic rats. This can also be achieved by increasing endogenous cannabinoid tone by inhibiting the breakdown of endocannabinoids or their transport. Increasing the levels of endocannabinoids allows them to interact with the CB 1 receptor.
Drugs that inhibit endocannabinoid breakdown are being developed clinically and may be available in the future for pain management. The other main target for cannabinoids in the body is called the CB 2 receptor which has an important role in the immune system.
Cannabinoids and diabetes
Chronic inflammation has long been known to play a key role in the development of insulin "Unlike insulin and other existing medications for diabetes, CBD may actually There are no major side effects of CBD, according to Rosenfield, which will not affect patients with diabetes .. Cholesterol help!. In drug-naive patients with type 2 diabetes, RIO showed a similar efficacy and . For therapeutic purposes, it is important that plant-derived CBD is also able to. Diabetes is a global health issue affecting nearly 10% of all adults, and is on the rise. Therefore, it is crucial to have more treatment options available to patients to other metabolic parameters like cholesterol levels and waist circumference. THC and CBD) had no significant effect on pain in 30 patients randomised to.